What is Leerink Partnrs’ Forecast for CNTA Q1 Earnings?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

A number of other equities analysts have also issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Morgan Stanley reissued an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Trading Down 4.9 %

Centessa Pharmaceuticals stock opened at $15.81 on Wednesday. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09. The stock has a market capitalization of $2.08 billion, a PE ratio of -10.33 and a beta of 1.54. The firm has a 50 day simple moving average of $16.51 and a 200-day simple moving average of $16.43. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,122,852.64. The trade was a 5.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Karen M. Anderson sold 6,471 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at $915,868.92. The trade was a 10.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,168 shares of company stock valued at $4,316,568. 11.59% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Centessa Pharmaceuticals during the third quarter valued at approximately $2,834,000. Wellington Management Group LLP acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth $1,609,000. State Street Corp acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at $777,000. Ally Bridge Group NY LLC purchased a new position in Centessa Pharmaceuticals in the third quarter valued at about $4,951,000. Finally, Lord Abbett & CO. LLC acquired a new position in Centessa Pharmaceuticals in the 3rd quarter worth about $4,305,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.